James M Foran MD
Hematologic Oncology
Associate Professor of Oncology, Mayo Clinic Cancer Center, Mayo Clinic Florida
Join to View Full Profile
4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 904-953-2000
Dr. Foran is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1995
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
University of ManitobaClass of 1990
Certifications & Licensure
FL State Medical License 2011 - 2027
AL State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification FirstNet (Clinical), Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2013-2015, 2017
Clinical Trials
- Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia Start of enrollment: 2004 Jan 01
- Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Publications & Presentations
PubMed
- Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.Talha Badar, Ludovica Marando, Eric Latorre, Terra Lasho, Francyess Denis Olivia
Blood Advances. 2026-03-10 - Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance.Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic
British Journal of Haematology. 2026-02-25 - Exposure to Agent Orange and Association with Myelodysplastic Syndromes.Mikkael A Sekeres, Amy E DeZern, Michael Otterstatter, Eric Padron, Tareq Al Baghdadi
Blood Advances. 2026-02-24
Journal Articles
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
Abstracts/Posters
- Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS StudyJames M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary MyelofibrosisJames M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Friday Scientific Workshop on Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Actinium Pharmaceuticals, Inc. To Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRApril 19th, 2022- Pulling Back the Curtain: Uma Borate, MDAugust 2nd, 2021
New Integrated Clinical Studies UnitDecember 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
